
NVCT
Healthcare · Biotechnology · $696.0M market cap
$20.24+0.01 (+0.0%)Nov 13, 4:00 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -59.5% over 90 days · 30-day revisions 1 up, 1 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 4, 2026 | Before the open | -0.22 | -1.02 | -363.6% |
| Aug 4, 2026 | Before the open | -0.25 | -0.30 | -20.0% |
| May 5, 2026 | Before the open | -0.31 | -0.26 | +16.1% |
| Feb 11, 2026 | Before the open | -0.31 | -0.31 | 0.0% |
| Nov 4, 2025 | Before the open | -0.25 | -0.44 | -76.0% |
| Aug 5, 2025 | Before the open | -0.25 | -0.30 | -20.0% |
| May 6, 2025 | Before the open | -0.25 | -0.27 | -8.0% |
| Feb 25, 2025 | Time not confirmed | -0.26 | -0.35 | -36.3% |
| Nov 5, 2024 | Before the open | -0.25 | -0.24 | +4.0% |
| Aug 6, 2024 | Before the open | -0.31 | -0.26 | +16.1% |
| May 7, 2024 | After the close | -0.39 | -0.25 | +35.9% |
| Mar 5, 2024 | Before the open | -0.36 | -0.41 | -13.9% |
| Nov 8, 2023 | Before the open | -0.34 |
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry…
| -0.37 |
| -8.8% |
| Aug 9, 2023 | After the close | -0.21 | -0.38 | -81.0% |
| May 10, 2023 | After the close | -0.45 | -0.27 | +40.0% |
| Mar 7, 2023 | Before the open | -0.38 | -0.49 | -28.9% |
| Nov 8, 2022 | Before the open | -0.27 | -0.42 | -55.6% |
| Aug 10, 2022 | After the close | -0.24 | -0.28 | -16.7% |
| May 12, 2022 | After the close | -0.22 | -0.32 | -45.5% |
| Mar 22, 2022 | Before the open | -0.85 | -0.48 | +43.5% |
| Oct 21, 2021 | Time not confirmed | — | -24.43 | — |